The global psoriatic arthritis treatment market is expected to reach USD 12.46 billion by 2027 - Arizton

The psoriatic arthritis treatment market portfolio contains a total of 25+ assets that are in various phases of development. Most industry-sponsored drugs in active clinical development for psoriatic arthritis are in the Phase III stage. The emerging therapeutics for psoriatic arthritis include Bimekizumab, Tildrakizumab, SHR-0302, Neihulizumab, and many others. Launching these novel emerging drugs will shift the PsA treatment paradigm in the near future. With more than 25 molecules in various stages of development, it is expected that new vendors are likely to enter the industry with a novel mechanism of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating psoriatic arthritis.

Psoriatic Arthritis: Clinical Trials Scenario
The clinical trial portfolio contains 150+ trials in various development phases. Most industry-sponsored drugs in active clinical development for PsA are in the Phase III stage. The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for psoriatic arthritis have been in the late phase of development, with 58% of trials in Phase II/III & III and only 41% in Phase Phase I-II.

MARKET DRIVERS & TRENDS
Increasing Adoption of Biological Therapies
Biological therapies such as anti-tumor necrosis factor (TNF) and anti-interleukin antibodies are widely used in the psoriatic arthritis treatment market. With Stelara being biologic approved for PsA in 2013, there is a demand for therapies with novel MOAs that are less immunogenic than current offerings. Many new classes of therapies are looking to enter the psoriatic arthritis treatment market over the next few years. The biologics such as interleukin inhibitors are making inroads into the psoriatic arthritis market owing to better clinical profile and convenient patient dosing.

Key Vendors
AbbVie Inc.
Johnson & Johnson
UCB SA
Amgen
Bristol-Myers Squibb
Pfizer
Eli Lilly and Company
Novartis

Other Prominent Vendors
Samsung Bioepis
Boehringer Ingelheim
Mylan
Merck & Co., Inc
Coherus BioSciences, Inc
Key Emerging Vendors with Late Stage Pipeline Drugs
Sun Pharmaceuticals
Bausch Health Companies Inc
Jiangsu HengRui Medicine Co. Ltd
Biocad Biopharmaceutical
Meiji Holdings Co Ltd
Bio-Thera

Segmentation by Drug Class
TNF Inhibitors
Interleukin Inhibitors
NSAIDs
Other classes of Drugs

Segmentation by Disease Type
Spondylitis
Enthesitis
Dactylitis

Segmentation by Gender Type
Men
Women

Segmentation by Age Group
50 years and Below
50 years and Above

Segmentation by Severity Type
Moderate
Mild
Severe

Segmentation by Geography
North America
United States

APAC
China
Japan

Europe
U.K.
France
German
Italy
Spain

Know more: https://www.arizton.com/market-reports/psoriatic-arthritis-treatment-market

ABOUT ARIZTON:  

Arizton Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services. 

We offer comprehensive market research reports on industries such as consumer goods & retail technology, automotive and mobility, smart tech, healthcare, and life sciences, industrial machinery, chemicals, and materials, IT and media, logistics and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts. 

Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports. 

Call: +1-312-235-2040 
          +1 302 469 0707 
Mail: enquiry@arizton.com

This release was published on openPR.